Pseudohypoaldosteronism (PHA)

Other names
Types
Causes
Common symptoms and signs
Diagnostic tests
Non-pharmacological treatments (therapies & others)
Drug treatments
Dietary molecular supplements
Immunity booster / regenerative / stem-cell drugs
Surgeries / procedures
Preventions
When to see a doctor
What to eat / what to avoid
Frequently asked questions

Pseudohypoaldosteronism (PHA) is a group of rare conditions where the body makes aldosterone normally (often in high amounts) but kidney or other tissues do not respond to it. Because the signal is not heard, the kidneys do not reabsorb enough salt (sodium) and do not excrete enough potassium. This causes low blood sodium (hyponatremia), high blood potassium (hyperkalemia), and often metabolic acidosis, even though aldosterone levels are high and kidney filtration is usually normal. In babies, this can look like poor feeding, vomiting, dehydration, and failure to thrive. Some genetic forms also affect sweat glands, lungs, and the gut, leading to very salty sweat, recurrent chest infections, and widespread salt loss. Medscape+2Orpha+2

There are primary (genetic) forms and secondary (transient/acquired) forms. Primary forms include PHA type 1 (renal/“autosomal dominant” due to mineralocorticoid receptor defects; and systemic/“autosomal recessive” due to epithelial sodium channel defects) and PHA type 2 (Gordon syndrome), which is a different disorder with hypertension and hyperkalemia due to increased sodium-chloride reabsorption in the distal tubule. Secondary PHA occurs mostly in infants with urinary tract infection (UTI) and/or urinary tract malformations, and resolves when the underlying problem is treated. Frontiers+4Orpha+4Orpha+4

Other names

PHA (pseudohypoaldosteronism) – umbrella term. Medscape
Primary mineralocorticoid resistance – commonly used for PHA type 1. OUP Academic
Renal PHA1 / Autosomal dominant PHA1 (PHA1A) – kidney-restricted form from NR3C2 (mineralocorticoid receptor) variants. NCBI
Systemic or generalized PHA1 / Autosomal recessive PHA1 (PHA1B) – multi-organ salt wasting from ENaC subunit (SCNN1A/B/G) variants. NCBI+1
PHA2 / Gordon syndrome / Familial hyperkalemic hypertension – hyperkalemia with hypertension due to WNK1/WNK4/KLHL3/CUL3 variants. Genetic & Rare Diseases Info Center+1
Secondary (transient) PHA – aldosterone resistance triggered by UTI/urinary tract malformation/obstruction in infants. Frontiers+1

Types

PHA Type 1 – Renal/Autosomal Dominant (PHA1A)
This type is restricted to the kidney and usually improves with age. It is caused by loss-of-function variants in NR3C2, the mineralocorticoid receptor (MR) gene, so the kidney cannot “hear” aldosterone. Babies present with salt-wasting and hyperkalemic acidosis, but many older children and adults become minimally symptomatic; aldosterone may remain elevated. NCBI+1
PHA Type 1 – Systemic/Autosomal Recessive (PHA1B)
This more severe, lifelong form is due to inactivating variants in the epithelial sodium channel (ENaC) genes SCNN1A, SCNN1B, or SCNN1G. Because ENaC is expressed in kidney, colon, sweat and salivary glands, and airways, patients lose salt from multiple organs, have very salty sweat, recurrent respiratory infections, and persistent electrolyte problems that require high-dose sodium therapy. Orpha+1
PHA Type 2 (Gordon syndrome)
A distinct condition marked by hyperkalemia with hypertension and metabolic acidosis, often with low renin and normal or high aldosterone. It results from variants in WNK1, WNK4, KLHL3, or CUL3, which increase NCC (thiazide-sensitive) transporter activity; treatment with thiazide diuretics corrects the abnormality. Genetic & Rare Diseases Info Center
Secondary/Transient PHA (acquired)
Seen mostly in young infants during severe UTI, pyelonephritis, and/or urinary tract malformations/obstruction. Inflammation or high intrarenal pressures blunt aldosterone signaling in the tubules. The condition resolves when the infection/malformation is treated. Frontiers+1

Causes

NR3C2 (MR) loss-of-function variants → Renal PHA1 (autosomal dominant); kidney cannot respond to aldosterone. NCBI+1
SCNN1A variants (ENaC α-subunit) → systemic PHA1 with multi-organ salt wasting. PMC
SCNN1B variants (ENaC β-subunit) → systemic PHA1; recurrent hyperkalemia and salt loss. Frontiers
SCNN1G variants (ENaC γ-subunit) → systemic PHA1; severe neonatal presentation. OUP Academic
Compound ENaC variants (multiple subunits) → more severe systemic PHA1. OUP Academic
WNK1 variants → PHA2 with hyperkalemia + hypertension. Genetic & Rare Diseases Info Center
WNK4 variants → PHA2 with hyperkalemia + metabolic acidosis. Genetic & Rare Diseases Info Center
KLHL3 variants → PHA2D; often early-onset hypertension. National Organization for Rare Disorders
CUL3 variants → PHA2 subtype; severe, often pediatric hypertension. Genetic & Rare Diseases Info Center
Secondary PHA due to urinary tract infection (UTI) in infants. Frontiers
Secondary PHA due to urinary tract malformation (UTM) (e.g., VUR, posterior urethral valves). ScienceDirect
Secondary PHA due to obstructive uropathy/pyelonephritis. ScienceDirect
Secondary PHA associated with severe inflammatory renal injury (intrarenal “cytokine storm” effect). BioMed Central
Kidney transplant aldosterone resistance (down-regulated MR expression) – rare acquired aldosterone resistance. NCBI
Idiopathic secondary PHA (rare reports without UTI/UTM in neonates). J Clin Res Pediatr Endocrinol
Systemic PHA airway involvement (ENaC dysfunction) aggravates salt/water handling and respiratory infections (a disease-expression “cause” of severity). Orpha
Severe diarrheal sodium loss can unmask or worsen PHA in infants already predisposed (case-based). Pediatric Medicine
Prematurity with immature tubule function may amplify secondary PHA (observational pediatric series). Frontiers
Concurrent salt-losing nephropathies (rare overlaps) may present like or alongside PHA1 in infancy. Medscape
Rare MR functional defects (non-coding/promoter) documented in molecular series; phenotype renal PHA1. OUP Academic

Common symptoms and signs

Poor feeding and vomiting in early weeks of life, due to low sodium and high potassium. PMC
Dehydration (dry mouth, sunken eyes/fontanelle) from salt loss and low effective blood volume. Medscape
Failure to thrive / poor weight gain when salt wasting is persistent. Bioscientifica
Lethargy or unusual sleepiness, often from low sodium or acidosis. Medscape
Irritability (electrolyte shifts make babies uncomfortable). Medscape
Low or normal blood pressure in PHA1; high blood pressure in PHA2. Medscape+1
Muscle weakness or floppiness from hyperkalemia/acidosis. Medscape
Cardiac rhythm problems (dangerous with high potassium), sometimes seen on ECG. Medscape
Seizures in severe hyponatremia. Medscape
Very salty sweat and prickly heat-like rash in systemic PHA1. Orpha
Recurrent chest infections or cough/wheeze due to ENaC dysfunction in airways (systemic PHA1). Orpha+1
Frequent wet diapers / high urine sodium despite dehydration (paradoxical salt loss). Medscape
Abdominal pain or vomiting during UTIs in secondary PHA. Frontiers
Heat intolerance (losing salt in sweat) in systemic PHA1. Orpha
Symptoms starting in infancy for PHA1; later childhood/adolescence for many PHA2 cases. MedlinePlus+1

Diagnostic tests

A) Physical examination (bedside)

General hydration check (skin turgor, mucous membranes, sunken eyes/fontanelle) to gauge dehydration severity from salt loss. Medscape
Vital signs (temperature, heart rate, respiratory rate, blood pressure) to distinguish low/normal BP in PHA1 from hypertensive PHA2. Medscape+1
Growth assessment (weight, length, weight-for-age) to identify failure to thrive. Bioscientifica
Skin inspection for salt crystals/rash and signs of heat injury in systemic PHA1. Orpha
Respiratory exam for wheeze/crackles suggesting airway involvement or intercurrent infection in systemic PHA1. Orpha

B) “Manual”/bedside clinical tests

Orthostatic (supine-to-standing) BP/HR to look for volume depletion in PHA1; not expected in PHA2. Medscape
Bedside ECG to screen immediately for hyperkalemia-related arrhythmias (peaked T waves, QRS widening). Medscape
Urine dipstick and microscopy to screen for UTI (leukocyte esterase/nitrites) in suspected secondary PHA. Frontiers

C) Laboratory and pathological tests

Serum electrolytes: low Na, high K are the hallmark; chloride and bicarbonate help judge metabolic acidosis. Medscape
Arterial/venous blood gas to confirm normal anion gap metabolic acidosis in PHA1 or PHA2. Medscape
Plasma renin activity and serum aldosterone: both typically elevated in PHA1 (resistance), whereas renin is low and aldosterone normal/high in many PHA2. Medscape+1
Urine sodium and fractional excretion of sodium (FENa): inappropriately high despite hyponatremia in salt-wasting PHA1. Medscape
Urine potassium indices (e.g., transtubular potassium gradient, TTKG): inappropriately low K secretion in the face of hyperkalemia suggests aldosterone pathway resistance. Medscape
Inflammatory markers and culture/urine culture if secondary PHA is suspected, to document UTI. Frontiers
Sweat electrolyte testing (Na/Cl): often very high in systemic PHA1; helps explain heat intolerance and dehydration; rule out/consider CF differential. Orpha
Genetic testing panels for NR3C2 (PHA1A) and SCNN1A/B/G (PHA1B); and WNK1/WNK4/KLHL3/CUL3 when PHA2 is suspected; confirms the form and guides counseling. E-APEM+2MedlinePlus+2
Cortisol/ACTH to exclude primary adrenal insufficiency (a different cause of hyperkalemia and hyponatremia with low aldosterone). Medscape
Renal function (creatinine), urinalysis to ensure GFR is preserved and to look for tubulointerstitial injury. Medscape

D) Electrodiagnostic studies

12-lead ECG for hyperkalemia changes and rhythm monitoring; repeat after treatment to ensure stabilization. Medscape

E) Imaging tests

Renal and urinary tract imaging (renal/bladder ultrasound; consider voiding cystourethrogram if reflux suspected) to find malformations/obstruction that drive secondary PHA; treatable causes that often resolve the electrolyte disorder. Chest imaging may be used if respiratory complications are suspected in systemic PHA1. ScienceDirect+1

Non-pharmacological treatments (therapies & others)

Each item includes: brief description (what to do), purpose, and mechanism (how it helps).

Emergency hyperkalemia protocol (hospital setting). Treat dangerous potassium quickly with cardiac stabilization and potassium-lowering steps. Purpose: prevent arrhythmias and death. Mechanism: calcium protects the heart; insulin/glucose, β-agonist nebulization, and bicarbonate shift potassium into cells; resins or dialysis remove potassium. FDA Access Data+2FDA Access Data+2
Aggressive IV isotonic fluids during salt-wasting crises. Use 0.9% sodium chloride to restore volume and sodium. Purpose: correct dehydration and hyponatremia. Mechanism: replaces sodium and water, improving perfusion and kidney delivery of filtered electrolytes. FDA Access Data
Oral sodium supplementation (between crises). In PHA1, frequent oral sodium chloride (sometimes very high doses in systemic ENaC disease) to keep sodium normal. Purpose: prevent recurrent dehydration and failure to thrive. Mechanism: replaces the sodium the kidney is losing. jcpres.com+1
Low-potassium diet (medical nutrition therapy). Limit high-potassium foods when hyperkalemia recurs. Purpose: reduce potassium load. Mechanism: lowers gut potassium absorption to reduce serum levels. Medscape
Dietitian-guided infant feeding plan. Adjust formula/breast-milk fortification and sodium content; monitor growth curves. Purpose: support weight gain while controlling electrolytes. Mechanism: matches calorie, fluid, and sodium needs to ongoing renal losses. jcpres.com
Frequent outpatient monitoring (electrolytes/acid-base). Check Na/K/CO₂ often, especially during illness. Purpose: catch swings early. Mechanism: lab-guided dose titration of salt, binders, and diuretics. jcpres.com
Sick-day rules. During vomiting/diarrhea, increase oral sodium, seek care early, and recheck labs. Purpose: avoid rapid decompensation. Mechanism: anticipates higher sodium losses and prerenal azotemia. jcpres.com
Avoidance of potassium-raising drugs. Avoid ACEi/ARB, spironolactone, eplerenone, amiloride, trimethoprim, NSAIDs where possible. Purpose: reduce iatrogenic hyperkalemia. Mechanism: these agents impair renal K⁺ excretion or shift K⁺ out of cells. Medscape
Nebulized β-agonist (as a non-pill adjunct). Albuterol via nebulizer during acute hyperkalemia lowers K⁺ within minutes. Purpose: quick, noninvasive potassium shift. Mechanism: β₂ stimulation drives K⁺ into cells via Na⁺/K⁺-ATPase. PubMed+1
Bicarbonate therapy when acidotic. Correct metabolic acidosis to help potassium move intracellularly and improve ENaC function. Purpose: lower K⁺ and buffer acid. Mechanism: raises systemic pH; alkalemia shifts K⁺ intracellularly. FDA Access Data
Oral rehydration timing and spacing of meds. Separate oral potassium binders from other meds to prevent binding interactions. Purpose: maintain efficacy of all agents. Mechanism: patiromer label advises ≥3-hour separation from other oral drugs. FDA Access Data
Salt-enriched weaning foods (older infants). Use low-potassium, higher-sodium recipes while monitoring BP and labs. Purpose: dietary partner to sodium tablets. Mechanism: compensates ongoing renal salt loss. jcpres.com
Home action plan for caregivers. Written plan: red-flag symptoms, dosing charts, and when to go to ER. Purpose: rapid, consistent response. Mechanism: reduces delay in treating emerging crisis. jcpres.com
Thiazide-responsive plan for PHA2. Lifestyle sodium moderation plus thiazide first-line for BP and K⁺. Purpose: turn off the overactive NCC pathway. Mechanism: thiazides block distal NCC, enhancing Na⁺ and K⁺ excretion. NCBI+1
Sweat/skin care in systemic PHA1. ENaC dysfunction increases salt loss in sweat; prevent dermatitis and dehydration. Purpose: comfort and fluid balance. Mechanism: reduces cutaneous salt/water loss irritation. MedlinePlus
Infection-prevention basics. Vaccinations on schedule; early treatment of gastroenteritis. Purpose: avoid triggers of electrolyte decompensation. Mechanism: fewer dehydration episodes → fewer crises. jcpres.com
Education to avoid salt substitutes (often potassium-based). Purpose: prevent unrecognized K⁺ loading. Mechanism: common salt substitutes contain KCl. Medscape
Dialysis (as rescue). For refractory, life-threatening hyperkalemia or renal failure. Purpose: remove potassium directly. Mechanism: diffusion and convection clear K⁺ from blood. Medscape
Genetic counseling. Explain inheritance (AD NR3C2 vs AR ENaC; PHA2 genes). Purpose: family planning and early testing. Mechanism: targeted testing and anticipatory care. MedlinePlus+1
Transition-of-care planning. Structured handover from pediatrics to adult nephrology for persistent cases. Purpose: maintain adherence and monitoring. Mechanism: prevents loss to follow-up. jcpres.com

Drug treatments

For each, I note class, typical dosing/time (from label where available), purpose/mechanism, and key side effects/warnings. Some uses here (e.g., insulin/glucose for hyperkalemia) are standard of care but off-label for PHA specifically; labels are cited for safety and dosing fundamentals.

Patiromer (VELTASSA). Potassium binder. Dose/time: start 8.4 g once daily, titrate; separate ≥3 h from other oral meds; not for emergency use due to delayed onset. Purpose/mechanism: binds K⁺ in colon to lower serum K⁺. Side effects: constipation, hypomagnesemia; drug-binding interactions. FDA Access Data+1
Sodium zirconium cyclosilicate (LOKELMA). Potassium binder. Dose/time: 10 g TID up to 48 h for initial correction; then 10 g daily; not for emergency treatment. Purpose/mechanism: exchanges K⁺ for H⁺/Na⁺ in gut; lowers K⁺. Side effects: edema (sodium load). FDA Access Data+1
Sodium polystyrene sulfonate (KAYEXALATE). Potassium binder. Dose/time: per label; avoid in neonates orally; risk of colonic necrosis esp. with sorbitol. Purpose/mechanism: exchanges Na⁺ for K⁺ in colon. Side effects: GI necrosis, constipation, hypokalemia, sodium load. FDA Access Data+1
Hydrochlorothiazide (HCTZ). Thiazide diuretic (first-line for PHA2). Dose: label-guided antihypertensive dosing. Purpose/mechanism: blocks NCC in distal tubule → increases Na⁺/K⁺ excretion; lowers BP and K⁺ in PHA2. Side effects: hyponatremia, hypokalemia, hyperuricemia, photosensitivity. FDA Access Data+1
Chlorthalidone. Thiazide-like diuretic. Dose: per label (e.g., 12.5–25 mg daily). Purpose/mechanism: potent, long-acting NCC blocker effective in Gordon syndrome. Side effects: same class risks; monitor electrolytes/glucose/uric acid. FDA Access Data
Furosemide (LASIX). Loop diuretic. Dose: label-based; titrate to diuresis. Purpose/mechanism: increases distal sodium delivery and potassium excretion; useful if volume overloaded or for acute K⁺ reduction with fluids. Side effects: dehydration, electrolyte loss, ototoxicity at high doses. FDA Access Data
Calcium gluconate (IV). Cardiac membrane stabilizer in severe hyperkalemia. Dose: label-specific; slow IV administration. Purpose/mechanism: stabilizes myocardial cells, buying time while K⁺ is lowered. Side effects: tissue injury with extravasation; avoid mixing with bicarbonate solutions. FDA Access Data+1
Regular insulin (IV) with dextrose. Shifts K⁺ into cells rapidly. Dose: hospital protocols (e.g., 10 units IV regular insulin with 25 g dextrose); labels provide insulin/dextrose safety info. Purpose/mechanism: stimulates Na⁺/K⁺-ATPase → intracellular K⁺ shift. Side effects: hypoglycemia—monitor glucose. FDA Access Data+1
Albuterol nebulization. β₂-agonist. Dose: hyperkalemia studies often 10–20 mg nebulized; labels give administration/safety details. Purpose/mechanism: β₂ stimulation drives K⁺ into cells; adjunct to insulin/glucose. Side effects: tremor, tachycardia; monitor in arrhythmia. PubMed+1
Sodium bicarbonate (IV). Alkali therapy when acidotic. Dose: label-guided; titrate to pH/CO₂. Purpose/mechanism: raises pH, shifting K⁺ intracellularly and improving acidosis. Side effects: volume/Na⁺ load, overshoot alkalosis. FDA Access Data
0.9% Sodium chloride (IV). Volume and sodium replacement. Dose: label-guided; individualized by weight and dehydration severity. Purpose/mechanism: corrects salt-wasting shock; improves renal K⁺ handling. Side effects: fluid overload if excessive. FDA Access Data
Dextrose/saline infusions (various strengths). Supportive fluid therapy. Purpose/mechanism: restore fluid/electrolyte balance and allow safe insulin delivery. Side effects: hyperglycemia, electrolyte shifts. FDA Access Data
Oral sodium chloride tablets (1 g). Electrolyte replenisher. Dose: individualized; often multiple grams/day in systemic PHA1. Purpose/mechanism: replaces ongoing salt losses. Side effects: edema/HTN risk—monitor. dailymed.nlm.nih.gov
Fludrocortisone. Mineralocorticoid. Role: can help some renal (NR3C2) PHA1 but is usually ineffective in systemic ENaC PHA1; may be used during diagnostic uncertainty. Side effects: hypertension, edema, hypokalemia. Mechanism: attempts to amplify mineralocorticoid signaling. Merck Manual+1
Sodium chloride parenteral solutions (various). For dilution and IV therapy as per label. Purpose/mechanism: controlled sodium delivery in hospital care. Side effects: as above. FDA Access Data
Insulin protocols (safety). See human regular insulin labels. Purpose/mechanism: reinforce safe dosing and hypoglycemia monitoring when used for K⁺ shift. Side effects: hypoglycemia. FDA Access Data
Adjunct loop + isotonic fluid (acute K⁺ lowering). Combine furosemide with normal saline for kaliuresis when volume replete. Purpose/mechanism: increases distal sodium delivery → K⁺ excretion. Side effects: dehydration/electrolyte loss. FDA Access Data
Monitoring for binder interactions. Patiromer separation ≥3 h; similar caution with SPS. Purpose/mechanism: avoid reduced absorption of other meds. Side effects: therapeutic failure if not separated. FDA Access Data+1
Albuterol HFA (inhaler) safety notes. Potassium can drop with high doses; monitor. Purpose/mechanism: supports nebulized therapy data; label highlights K⁺ changes and cardiac cautions. Side effects: hypokalemia, tachycardia. FDA Access Data
Clinical evidence anchor for albuterol in hyperkalemia. Dialysis patients study and modern kinetic work. Purpose/mechanism: documents dose-dependent K⁺ fall and safety considerations. Side effects: as above. PubMed+1

Dietary molecular supplements

There are no special “molecular supplements” proven to fix PHA itself; care is about salt in, potassium down, fluids right. Below are nutrition aids often used clinically to support management (not to replace medicines). Always individualize with a dietitian and clinician.

Oral Sodium Chloride (NaCl) powder/tablets. Dose: by clinician; often multi-gram/day in systemic PHA1. Function/mechanism: replaces renal sodium losses; prevents hyponatremia/dehydration. dailymed.nlm.nih.gov
Glucose polymers (energy supplement). Dose: per weight/needs. Function: extra calories to support growth. Mechanism: improves weight gain, reducing catabolic stress during salt-wasting phases. jcpres.com
Oral rehydration solution (ORS) strategy. Dose: per diarrheal losses. Function: balanced water/electrolyte intake. Mechanism: prevents dehydration and sodium deficits during illness. jcpres.com
Low-potassium fortifiers/recipes. Function: reduce dietary K⁺ load. Mechanism: less intestinal K⁺ absorption → lower serum K⁺. Medscape
Sodium bicarbonate (oral, selected cases). Dose: as per labs and clinician. Function: corrects chronic acidosis. Mechanism: raises serum bicarbonate; may modestly aid K⁺ control. FDA Access Data
Vitamin D and calcium (standard pediatric needs). Function: bone health during chronic illness. Mechanism: supports mineralization; not disease-specific for PHA. (Use per pediatric guidelines.) jcpres.com
Iron supplementation if deficient. Function: correct iron-deficiency anemia if present. Mechanism: restores hemoglobin, improves growth/energy. (Labs guide therapy.) jcpres.com
Iodine-adequate diet. Function: routine thyroid support in infants. Mechanism: ensures normal growth and development; not PHA-specific. jcpres.com
Protein-adequate feeding plan. Function: catch-up growth. Mechanism: supports lean mass and immune function during chronic salt loss. jcpres.com
Fiber-balanced diet. Function: avoid binder-related constipation (patiromer/SZC/SPS). Mechanism: improves bowel motility while monitoring K⁺ content of produce. FDA Access Data

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity booster,” regenerative, or stem-cell drugs for treating pseudohypoaldosteronism. Using such products for PHA would be unsupported and potentially unsafe. The proven, guideline-consistent approach is salt replacement, potassium control, and (for PHA2) thiazides, with emergency hyperkalemia protocols when needed. If a patient with PHA has a separate condition that truly requires immunotherapy or cell therapy, that should be managed under specialist care for that diagnosis—not for PHA. MedlinePlus+1

Surgeries / procedures

There is no disease-specific surgery that corrects PHA. However, procedures may be used for complications or rescue:

Temporary hemodialysis catheter placement for dialysis in refractory, life-threatening hyperkalemia. Why: rapidly remove K⁺. Medscape
Peritoneal dialysis catheter in infants if chronic dialysis ever becomes necessary due to severe, recurrent crises and kidney injury. Why: continuous home-based K⁺ removal when indicated. Medscape
Central venous access in unstable infants for reliable fluids/electrolytes and IV medications. Why: secure resuscitation and therapy delivery. FDA Access Data
Enteral feeding access (NG/PEG) in severe failure to thrive when oral intake is not enough. Why: ensure calories and sodium delivery. jcpres.com
Cardiac monitoring/defibrillation capability in severe hyperkalemia. Why: immediate response to arrhythmias. FDA Access Data

Preventions

Keep routine follow-up and frequent labs to adjust salt/binders/diuretics. jcpres.com
Sick-day plan (extra NaCl; early IV fluids if vomiting/diarrhea). jcpres.com
Avoid K⁺-raising medicines (ACEi/ARB, K-sparing diuretics, NSAIDs, high-dose trimethoprim). Medscape
Dietitian-led low-K⁺ meal plan; avoid KCl salt substitutes. Medscape
Ensure vaccinations and prompt infection care. jcpres.com
Teach caregivers about red-flags (poor feeding, lethargy, vomiting, arrhythmia symptoms). jcpres.com
Separate patiromer from other oral meds by ≥3 hours. FDA Access Data
Monitor blood pressure (especially PHA2 and those on fludrocortisone). NCBI
Regular growth monitoring in infants; adjust calories and sodium. jcpres.com
Keep an updated emergency letter with the hyperkalemia protocol for ER teams. FDA Access Data

When to see a doctor

Go to the emergency department immediately for poor feeding, persistent vomiting, unusual sleepiness, fainting, muscle weakness, palpitations, or seizures—these can signal dangerous hyperkalemia or severe hyponatremia. Families should bring their action plan and medication list. Routine care with nephrology/pediatrics is needed for dose adjustments, growth checks, and lab follow-up. jcpres.com

What to eat / what to avoid

Eat more / include: sodium-adequate meals as prescribed; low-potassium fruits/vegetables; balanced calories with adequate protein; fiber to prevent constipation if using binders; plenty of fluids during hot weather or illness (per clinician). Avoid/limit: potassium-rich foods when K⁺ is high; salt substitutes containing KCl; over-the-counter NSAIDs; herbal supplements that may raise K⁺; large unplanned fluid loads without medical advice if you have heart or kidney issues. Medscape

Frequently asked questions

Is PHA caused by low aldosterone? No—aldosterone is normal/high; the body resists it. MedlinePlus
Which babies have the worst symptoms? Systemic PHA1 (ENaC) tends to be more severe and long-lasting. MedlinePlus
Does it get better? Renal PHA1 often improves in early childhood; systemic PHA1 usually persists. MedlinePlus
What is PHA2/Gordon syndrome? A form with high BP + high K⁺ that improves with thiazides. NCBI
Can fludrocortisone fix PHA1? Sometimes helps renal PHA1 but generally fails in systemic PHA1. Merck Manual+1
What’s the fastest way to lower dangerous K⁺? Hospital hyperkalemia protocol: calcium for the heart, insulin/glucose, albuterol, bicarbonate (if acidotic), plus binders or dialysis. FDA Access Data+1
Are potassium binders safe for children? Patiromer label covers ≥12 years; others require specialist judgment. Always follow pediatric nephrology advice. FDA Access Data
Do we need a special “supplement” to cure PHA? No. Focus on salt in, K⁺ down, fluids right, and medicines. MedlinePlus
Why separate patiromer from other pills? It binds many medicines in the gut—keep ≥3 h apart. FDA Access Data
Can we use salt substitutes? Avoid KCl-based substitutes—they raise potassium. Medscape
What tests confirm PHA? Electrolytes, acid-base, renin/aldosterone pattern, and genetic testing (NR3C2 vs ENaC; WNK/KLHL3/CUL3 for PHA2). MedlinePlus+1
Is PHA2 a kidney failure disease? Not at first; GFR can be normal, but hypertension needs control. NCBI
What triggers crises? Gastroenteritis, heat, missed sodium, or high-K⁺ foods/meds. jcpres.com
Are nebulized β-agonists really effective for K⁺? Yes—studies show a prompt K⁺ drop; combine with standard measures. PubMed+1
Can adults have PHA? Yes—PHA2 often presents later; adult survivors of PHA1 may still need sodium and monitoring. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.